Trial Profile

Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bulevirtide (Primary) ; Peginterferon alfa
Indications Hepatitis B; Hepatitis D
Focus Proof of concept; Therapeutic Use
Sponsors Hepatera

Most Recent Events

16 Aug 2017 Status changed from active, no longer recruiting to completed.
15 Nov 2016 Final results presented at The Liver Meeting 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases
27 Apr 2016 Interim results published in the Journal of Hepatology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com